Features

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® summarized the latest literature on the multidisciplinary care approach for patients living with spinal muscular atrophy.

Cleveland Clinic experts Trishul Kapoor, MD, and Osama Kashlan, MD, discussed how advanced diagnostics, basivertebral nerve ablation, endoscopic surgery, and neuromodulation unite to ease chronic back pain.

Spinogenix’s codabakalner, an investigational BK channel modulator, is currently being evaluated in CLARITY, a phase 2b/3 trial for the treatment of patients with Fragile X syndrome.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.

The ongoing phase 3 RELIEVE trial investigates the efficacy and safety of remibrutinib in patients with generalized myasthenia gravis who are on stable standard-of-care treatment.

Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.

FACT, an ongoing trial, evaluates the efficacy of efgartigimod alfa injection versus high-dose intravenous methylprednisolone in a cohort patients with neuromyelitis optica spectrum disorder.

GLP-1 receptor agonists show growing relevance in neurology, with strongest evidence in stroke prevention and obstructive sleep apnea and emerging signals in idiopathic intracranial hypertension and migraine.

Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.

Machine learning will only transform clinical neurology if predictive accuracy is matched by usability, transparency, and active physician involvement in the design and implementation of tools that support patient care.

Experts Laura Saucier, MD, MSc, and Jonathan Santoro, MD, examined pediatric MOGAD phenotypes, highlighting how variability in clinical presentation may influence treatment responses and inform individualized care strategies.

In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

The POLARIS program includes 3 ongoing phase 1/2 clinical trials investigating the efficacy and safety of investigational gene therapy EXT101 in patients with SCN1A postive Dravet syndrome.

Since paraneoplastic neurologic syndromes remain underrecognized in oncology, experts recently discussed diagnostic challenges, treatment strategies, and the need for clinical vigilance.

Global site reactivation for the MAGNITUDE-2 trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy is underway, with enrollment completion expected in the second half of 2026.

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Salvia BioElectronics’ PRIMUS system, currently being assessed in a clinical trial, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.

Portable optical blood flow monitors can enhance prehospital stroke diagnosis, enabling faster, accurate triage for large vessel occlusions and improving patient outcomes.